

## **ALLIGATOR BIOSCIENCE RESOLVES ON CONVERSION OF SERIES C SHARES INTO ORDINARY SHARES FOR DELIVERY TO PARTICIPANTS IN INCENTIVE PROGRAM**

The board of directors of Alligator Bioscience AB ("Alligator") has on 3 December 2024 resolved to convert 170,681 series C shares into ordinary shares for delivery of shares to participants in the long-term incentive program in the form of a performance-based share saving program that was adopted at the annual general meeting held on 1 June 2021 ("LTI 2021").

The board of directors of Alligator has, in accordance with the provisions of LTI 2021, resolved to convert 170,681 series C shares for allotment of 170,681 ordinary shares to the participants in LTI 2021, where 22,650 ordinary shares were allotted to the CEO of Alligator and 148,031 ordinary shares were allotted to other participants. In total, 31 participants have been allotted ordinary shares in LTI 2021.

The number of outstanding shares in Alligator, after the registration of the above-mentioned conversion of series C shares into ordinary shares, still amounts to a total of 758,989,086 shares, of which 758,209,917 are ordinary shares with one vote each and 779,169 are series C shares with 1/10 vote each. All series C shares are held by Alligator. The total number of votes in Alligator amounts to 758,287,833.9.

### **For further information, please contact:**

---

Søren Bregenholt, CEO  
E-mail: [soren.bregenholt@alligatorbioscience.com](mailto:soren.bregenholt@alligatorbioscience.com)  
Phone: +46 (0) 46 540 82 00

---

*The information was submitted for publication, through the agency of the contact person set out above, at 12:15 p.m. CET on December 3, 2024.*

### **Attachments**

---

**Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program**